Selecting antibacterials for outpatient parenteral antimicrobial therapy: Pharmacokinetic-pharmacodynamic considerations

Clinical Pharmacokinetics

Volumn 42, Issue 9, 2003, Pages 793-817

  Slavik, Richard S ^b   Jewesson, Peter J ^a  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFACLOR; CEFAZOLIN; CEFIXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; CLOXACILLIN; DALFOPRISTIN PLUS QUINUPRISTIN; DOXYCYCLINE; ERYTHROMYCIN; GENTAMICIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; METRONIDAZOLE; NORFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; UNINDEXED DRUG; VANCOMYCIN;

ANTIMICROBIAL THERAPY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SENSITIVITY; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; OUTPATIENT CARE; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW;

AMBULATORY CARE; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CANADA; HUMANS; INFUSIONS, PARENTERAL;

EID: 0043165081     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200342090-00002     Document Type: Review

References (161)

1. Rucker RW, Harrison GM. Outpatient intravenous medications in the management of cystic fibrosis. Pediatrics 1974; 54: 358-60
2. Stiver HG, Telford GO, Mossey JM. Intravenous antibiotic therapy at home. Ann Intern Med 1978; 89: 690-3
3. Antoniskis A, Anderson BC, Van Volkinberg EL, et al. Feasibility of outpatient self-administration of parenteral antibiotics. West J Med 1978; 128: 203-6
4. Stiver HG, Trosky SK, Cote DD, et al. Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. CMAJ 1982; 127: 207-11
5. Poretz DM, Eron LJ, Goldenberg RI, et al. Intravenous antibiotic therapy in an outpatient setting. JAMA 1982; 248: 336-9
6. Balinsky W, Nesbitt S. Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. Am J Med 1989; 87: 1-5
7. Poretz DM, editor. Outpatient use of intravenous antibiotics. Am J Med 1994; 97 Suppl. 2A: 1-55
8. Stiver G, Wai A, Chase L, et al. Outpatient intravenous antibiotic therapy: the Vancouver Hospital experience. Can J Infect Dis 2000; 11 Suppl. A: 11A-4A
9. Williams DN, Rehm SJ, Tice AD, et al. Practice guidelines for community-based parenteral anti-infective therapy. Clin Infect Dis 1997; 25: 787-801
10. Wai AO, Frighetto L, Marra CA, et al. Cost analysis of an adult Outpatient Parenteral Antibiotic Therapy (OPAT) programme: a Canadian teaching hospital and Ministry of Health perspective. Pharmacoeconomics 2000; 18: 451-7
11. Thickson ND. Economics of home intravenous services. Pharmacoeconomics 1993; 3 (3): 220-7
12. Hindes R, Winkler C, Kane P, et al. Outpatient intravenous antibiotic therapy in Medicare patients: cost-savings analysis. Infect Dis Clin Pract 1995; 4: 211-7
13. Board N, Brennan NJ, Caplan GA. A randomised controlled trial of the costs of hospital as compared in the home for acute medical patients. Aust N Z J Public Health 2000; 24: 305-11
14. Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Drugs 2000; 59: 29-35
15. Goodfellow A, Wai A, Chan E, et al. Cost-benefit, quality of life and willingness to pay analyses of the Home IV Antibiotic program: a Canadian perspective [abstract]. The Canadian Association for Population Therapeutics Conference; 2001 Apr 1-3; Banff, Alberta
16. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 492-528
17. Karchmer AW. Cephalosporins. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 492-528
18. Chambers HF. Penicillins. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. Philadelphia: Churchill Livingston; 1995: 492-528
19. Gilbert DN. Aminoglycosides. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 492-528
20. Andes DR, Craig WA. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clin North Am 1998; 12: 849-60
21. Benet LZ, Oie S, Schwartz JB. Design and optimization of dosage regimens; pharmacokinetic data. (Appendix II). In: Hardman JG, Limbird LE, editors. Goodman and Gilman's The pharmacological basis of therapeutics. 9th ed. New York: McGraw-Hill Health Professions Division, 1996: 1707-92
22. Gilbert DN, Moellering RC, Sande MA. The Sanford guide to antimicrobial therapy. 31st ed. Hyde Park, Vermont: Antimicrobial Therapy Inc., 2001: 56-7
23. Marra F, Jewesson PJ. Vancomycin serum concentration monitoring: the middle ground is best. Clin Drug Investig 1996; 12: 105-18
24. Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet 2001; 40: 169-87
25. Manzella JP. Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Phys 2001; 64: 1863-6
26. Jewesson PJ. Pharmaceutical, pharmacokinetic and other considerations for intravenous to oral stepdown therapy. Can J Infect Dis 1995; 6 Suppl. A: 11A-6A
27. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58 Suppl. 2: 29-36
28. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 247-64
29. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 233-46
30. Amsden GW, Schentag JJ. Tables of antimicrobial agent pharmacology. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases. 5th ed. Philadelphia: Churchill Livingston, 1995: 279-306
31. Lietman PS. Pharmacokinetics of antimicrobial agents. In Mandell GL, editors. Principles and practice of infectious diseases. 3rd ed. New York: Churchill Livingstone, 1990: 228-30
32. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10
33. Stein GE. Pharmacokinetics and pharmacodynamics of newer fluoroquinolones. Clin Infect Dis 1996; 23 Suppl. 1: S19-24
34. Paladino JA, Sperry HE, Backes JM, et al. Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. Am J Med 1991; 91: 462-70
35. Paladino JA, Zimmer GS, Schentag JJ. The economic potential of dual individualisation methodologies. Pharmacoeconomics 1996; 10: 539-45
36. Frighetto L, Nickoloff D, Martinusen SM, et al. Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Ann Pharmacother 1992; 26: 1447-51
37. Malfair SC, Frighetto L, Nickoloff DM, et al. Evaluation of the use of cefuroxime and cefuroxime axetil in an intravenous-oral stepdown program. Ann Pharmacother 1996; 30: 337-42
38. Jewesson P. Cost-effectiveness and value of an IV switch. Pharmacoeconomics 1994; 5 Suppl. 2: 20-6
39. Paladino JA. Is more than one quinolone needed in clinical practice? Ann Pharmacother 2001; 35: 1085-95
40. Pea F, Furlanut M. Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions. Clin Pharmacokinet 2001; 40: 833-68
41. Gregg CR. Drug interactions and anti-infective therapies. Am J Med 1999; 106: 227-37
42. Gillum JG, Israel DS, Polk RE. Pharmacokinetic drug interactions with antimicrobial agents. Clin Pharmacokinet 1993; 25: 450-82
43. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112
44. Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38 (1): 41-57
45. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf 1998; 18: 83-97
46. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915-28
47. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80
48. Pai MP, Graci DM, Amsden GW. Macrolide drug interactions: an update. Ann Pharmacother 2000; 34: 495-513.
49. Fish DN. Fluoroquinolone adverse effects and drug interactions. Pharmacotherapy 2001; 21: 253S-72S
50. Jewesson PJ. Overcoming antibiotic resistance: a physicians' guide. Can J CME 1998; 3: 137-50
51. Ackerman BH, Dello Buono FA. In vitro testing of antibiotics. Pharmacotherapy 1996; 16: 201-17
52. Hyatt JM, McKinnon PS, Zimmer GS, et al. The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin Pharmacokinet 1995; 28: 143-60
53. Schentag JJ, Strenkoski-Nix LC, Nix DE, et al. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 1998; 27: 40-6
54. White RL. What in vitro models of infection can and cannot do. Pharmacotherapy 2001; 21 (11 Pt 2): 292S-301S
55. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-96
56. Sanchez-Navarro A, Sanchez Recio MM. Basis of anti-infective therapy: pharmacokinetic-pharmacodynamic criteria and methodology for dual dosage individualisation. Clin Pharmacokinet 1999; 37: 289-304
57. Li RC, Zhu M, Schentag JJ. Achieving an optimal outcome in the treatment of infections: the role of clinical pharmacokinetics and pharmacodynamics of antimicrobials. Clin Pharmacokinet 1999; 37: 1-16
58. Levison ME. Pharmacodynamics of antibacterial drugs. Infect Dis Clin North Am 2000; 14: 281-91
59. Li RC. New pharmacodynamic parameters for antimicrobial agents. Int J Antimicrob Agents 2000; 13: 229-35
60. Gunderson BW, Ross GH, Ibrahim KH, et al. What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 2001; 21 (11 Pt 2): 302S-18S
61. Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 2001; 21 (11 Pt 2): 319S-30S
62. Schentag JJ, Gilliland KK, Paladino JA. What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001; 32 Suppl. 1: S39-46
63. Burgess DS. Pharmacodynamic principles of antimicrobial therapy in the prevention of resistance. Chest 1999; 115 (3 Suppl.): 19S-23S
64. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1990; 11: 319-26
65. Craig WA, Ebert SC. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis Suppl 1991; 74: 63-70
66. Spivey JM. The postantibiotic effect. Clin Pharm 1992; 11: 865-75
67. Verbist L. Relevance of antibiotic susceptibility testing for clinical practice. Eur J Clin Microbiol Infect Dis 1993; 12 Suppl. 1: S2-5
68. Schentag JJ, Smith IL, Swanson DJ, et al. Role for dual individualization with cefmenoxime. Am J Med 1984; 77: 43-50
69. Schentag JJ, Swanson DJ, Smith IL. Dual individualization: antibiotic dosage calculation from the integration of in-vitro pharmacodynamics and in-vivo pharmacokinetics. J Antimicrob Chemother 1985; 15 Suppl. A: 47-57
70. Schentag JJ, Nix DE, Adelman MH. Mathematical examination of dual individualization principles (I): relationships between AUC above MIC and area under the inhibitory curve for cefmenoxime, ciprofloxacin, and tobramycin. DICP 1991; 25: 1050-7
71. Schentag JJ, Nix DE, Forrest A, et al. AUIC: the universal parameter within the constraint of a reasonable dosing interval. Ann Pharmacother 1996; 30: 1029-31
72. Tumidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis 1998; 27: 10-22
73. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 1995; 22: 89-96
74. Craig WA. Antimicrobial resistance issues of the future. Diagn Microbiol Infect Dis 1996; 25: 213-7
75. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 255-9
76. Gilbert DN, Dworkin RJ, Raber SR, et al. Outpatient parenteral antimicrobial-drug therapy. N Engl J Med 1997; 337: 829-38
77. Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001; 45: 2643-7
78. Bodey GP, Ketchel SJ, Rodriguez V. A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients. Am J Med 1979; 67: 608-16
79. MacGowan AP, Bowker KE. Continuous infusion of beta-lactam antibiotics. Clin Pharmacokinet 1998; 35: 391-402
80. Burgess DS, Hastings RW, Hardin TC. Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion. Clin Ther 2000; 22: 66-75
81. Nicolau DP, Nightingale CH, Banevicius MA, et al. Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections. Antimicrob Agents Chemother 1996; 40: 61-4
82. Benko AS, Cappelletty DM, Kruse JA, et al. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother 1996; 40: 691-5
83. Hanes SD, Wood GC, Herring V, et al. Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 2000; 179: 436-40
84. Nicolau DP, McNabb J, Lacy MK, et al. Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia. Int J Antimicrob Agents 2001; 17: 497-504
85. McNabb JJ, Nightingale CH, Quintiliani R, et al. Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia. Pharmacotherapy 2001; 21: 549-55
86. Ambrose PG, Quintiliani R, Nightingale CH, et al. Continuous vs intermittent infusion of cefuroxime for the treatment of community-acquired pneumonia. Infect Dis Clin Pract 1998; 7: 463-70
87. Grant EM, Kuti JL, Nicolau DP, et al. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22: 471-83
88. MacGowan AP. Pharmacodynamics, pharmacokinetics, and therapeutic drug monitoring of glycopeptides. Ther Drug Monit 1998; 20: 473-7
89. Larsson AJ, Walker KJ, Raddatz JK, et al. The concentration-independent effect of monoexponential and biexponential decay in vancomycin concentrations on the killing of Staphylococcus aureus under aerobic and anaerobic conditions. J Antimicrob Chemother 1996; 38: 589-97
90. Duffull SB, Begg EJ, Chambers ST, et al. Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model. Antimicrob Agents Chemother 1994; 38: 2480-2
91. Cantoni L, Wenger A, Glauser MP, et al. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis 1989; 159: 989-93
92. Schaad UB, McCracken Jr GH, Nelson JD. Clinical pharmacology and efficacy of vancomycin in pediatric patients. J Pediatr 1980; 96: 119-26
93. Zimmermann AE, Katona BG, Plaisance KI. Association of vancomycin serum concentrations with outcomes in patients with gram-positive bacteremia. Pharmacotherapy 1995; 15: 85-91
94. Klepser ME, Kang SL, McGrath BJ, et al. Influence of vancomycin serum concentration on the outcome of gram-positive infections. Presented at The American College of Clinical Pharmacy Annual Winter Meeting; 1994 Feb 4-6; San Diego
95. Rybak MJ, Capelletty MJ, Ruffing RC, et al. Influence of vancomycin serum concentrations on the outcome of patients being treated for Gram-positive infections [abstract]. Abstracts of the 37th Intersci Conf on Antimicrobial Agents Chemother. 1997 Sep 28-Oct 1: A46
96. Edwards DJ, Pancorbo S. Routine monitoring of serum vancomycin concentrations: waiting for proof of its value. Clin Pharm 1987; 6: 652-4
97. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993; 27: 594-8
98. Moellering Jr RC. Monitoring serum vancomycin levels: climbing the mountain because it is there? [published erratum appears in Clin Infect Dis 1994; 19: 379]. Clin Infect Dis 1994; 18: 544-6
99. Cantu TG, Yamanaka-Yuen NA, Lietman PS. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 18: 533-43
100. Leader WG, Chandler MH, Castiglia M. Pharmacokinetic optimisation of vancomycin therapy. Clin Pharmacokinet 1995; 28: 327-42
101. Saunders NJ. Vancomycin administration and monitoring reappraisal. J Antimicrob Chemother 1995; 36: 279-82
102. Shalansky S. Rationalization of vancomycin serum concentration monitoring. Can J Hosp Pharm 1995; 48: 17-24
103. Begg EJ, Barclay ML, Kirkpatrick CM. The therapeutic monitoring of antimicrobial agents. Br J Clin Pharmacol 2001; 52 Suppl. 1: 35S-43S
104. Welty TE, Copa AK. Impact of vancomycin therapeutic drug monitoring on patient care. Ann Pharmacother 1994; 28: 1335-9
105. Fernandez de Gatta MD, Calvo MV, Hernandez JM, et al. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies. Clin Pharmacol Ther 1996; 60: 332-40
106. James JK, Palmer SM, Levine DP, et al. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother 1996; 40: 696-700
107. Klepser ME, Patel KB, Nicolau DP, et al. Comparison of bactericidal activities of intermittent and continuous infusion dosing of vancomycin against methicillin-resistant Staphylococcus aureus and Enterococcus faecalis. Pharmacotherapy 1998; 18: 1069-74
108. Lacy MK, Tessier PR, Nicolau DP, et al. Comparison of vancomycin pharmacodynamics (1g every 12 or 24 h) against methicillin-resistant staphylococci. Int J Antimicrob Agents 2000; 15: 25-30
109. Wysocki M, Thomas F, Wolff MA, et al. Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections. J Antimicrob Chemother 1995; 35: 352-4
110. Albanese J, Leone M, Bruguerolle B, et al. Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit. Antimicrob Agents Chemother 2000; 44: 1356-8
111. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7
112. Blaser J, Stone BB, Groner MC, et al. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31: 1054-60
113. Dudley MN, Blaser J, Gilbert D, et al. Combination therapy with ciprofloxacin plus azlocillin against Pseudomonas aeruginosa: effect of simultaneous versus staggered administration in an in vitro model of infection. J Infect Dis 1991; 164: 499-506
114. Lode H, Borner K, Koeppe P. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 1998; 27: 33-9
115. Drusano GL, Johnson DE, Rosen M, et al. Pharmacodynamics of a fluoroquinolone antimicrobial agent in a neutropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993; 37: 483-90
116. Leggett JE, Fantin B, Ebert S, et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-92
117. Peloquin CA, Cumbo TJ, Nix DE, et al. Evaluation of intravenous ciprofloxacin in patients with nosocomial lower respiratory tract infections: impact of plasma concentrations, organism, minimum inhibitory concentration, and clinical condition on bacterial eradication. Arch Intern Med 1989; 149: 2269-73
118. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81
119. Forrest A, Chodosh S, Amantea MA, et al. Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 Suppl. A: 45-57
120. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-9
121. Zhanel GG, Walters M, Laing N, et al. In vitro pharmacodynamic modelling simulating free serum concentrations of fluoroquinolones against multidrug-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2001; 47: 435-40
122. Ambrose PG, Grasela DM, Grasela TH, et al. Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001; 45: 2793-7
123. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of fluoroquinolones: focus on respiratory tract infections. Drugs 2002; 62: 13-59
124. Thomas JK, Forrest A, Bhavnani SM, et al. Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy. Antimicrob Agents Chemother 1998; 42: 521-7
125. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 Suppl. C: 29-40
126. Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-47
127. Bayer AS, Norman D, Kim KS. Efficacy of amikacin and ceftazidime in experimental aortic valve endocarditis due to Pseudomonas aemginosa. Antimicrob Agents Chemother 1985; 28: 781-5
128. Noone P, Parsons TM, Pattison JR, et al. Experience in monitoring gentamicin therapy during treatment of serious gram-negative sepsis. BMJ 1974; 1: 477-81
129. Moore RD, Smith CR, Lietman PS. The association of aminoglycoside plasma levels with mortality in patients with gram-negative bacteremia. J Infect Dis 1984; 149: 443-8
130. Moore RD, Smith CR, Lietman PS. Association of aminoglycoside plasma levels with therapeutic outcome in gram-negative pneumonia. Am J Med 1984; 77: 657-62
131. Deziel-Evans LM, Murphy JE, Job ML. Correlation of pharmacokinetic indices with therapeutic outcome in patients receiving aminoglycosides. Clin Pharm 1986; 5: 319-24
132. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9
133. Kashuba AD, Bertino Jr JS, Nafziger AN. Dosing of aminoglycosides to rapidly attain pharmacodynamic goals and hasten therapeutic response by using individualized pharmacokinetic monitoring of patients with pneumonia caused by gram-negative organisms. Antimicrob Agents Chemother 1998; 42: 1842-4
134. Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43: 623-9
135. Galloe AM, Graudal N, Christensen HR, et al. Aminoglycosides single or multiple daily dosing?: a meta-analysis on efficacy and safety. Eur J Clin Pharmacol 1995; 48: 39-43
136. Blaser J, Konig C. Once-daily dosing of aminoglycosides. Eur J Clin Microbiol Infect Dis 1995; 14: 1029-38
137. Barza M, Ioannidis JP, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312 (7027): 338-45
138. Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37: 645-63
139. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124: 717-25
140. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53: 1141-50
141. Freeman CD, Strayer AH. Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials. Pharmacotherapy 1996; 16: 1093-102
142. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 786-95
143. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24: 796-809
144. Rapp RP. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann Pharmacother 1998; 32: 785-93
145. Ebert S, Rikardsdottit S, Craig WA. Pharmacodynamic comparison of clarithromycin vs erythromycin [abstract]. In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1991: 509
146. Nightingale CH. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 1997; 16: 438-43
147. Craig W, Rikardsdottir S, Watanabe Y. In vivo and in vitro postantibiotic effects (PAEs) of azithromycin [abstract]. In: Program and abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1992: 45
148. Lewis RE, Klepser ME, Ernst EJ, et al. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrob Agents Chemother 1999; 43: 2005-9
149. Nix DE, Tyrrell R, Muller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39: 1848-52
150. Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study. Obstet Gynecol 1997; 89 (5 Pt 1): 699-703
151. Lamb HM, Figgitt DP, Faulds D. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs 1999; 58: 1061-97
152. Delgado Jr G, Neuhauser MM, Bearden DT, et al. Quinupristindalfopristin: an overview. Pharmacotherapy 2000; 20: 1469-85
153. Rybak MJ, Houlihan HH, Mercier RC, et al. Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother 1997; 41: 1359-63
154. Craig W, Ebert S. Pharmacodynamic activities of RP 59500 in an animal infection model. Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 1993 Oct 17-20; New Orleans, LA
155. Fantin B, Leclercq R, Merle Y, et al. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob Agents Chemother 1995; 39: 400-5
156. Aeschlimann JR, Rybak MJ. Pharmacodynamic analysis of the activity of quinupristin-dalfopristin against vancomycin-resistant Enterococcus faecium with differing MBCs via time-kill-curve and postantibiotic effect methods. Antimicrob Agents Chemother 1998; 42: 2188-92
157. Dresser LD, Rybak MJ. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials. Pharmacotherapy 1998; 18: 456-62
158. Perry CM, Jarvis B. Linezolid: a review of its use in the management of serious gram-positive infections. Drugs 2001; 61: 525-51
159. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001; 35: 566-75
160. Andes D, Van OML, Craig WA. Pharmacodynamic activity of a new oxazolidinone, linezolid, in an animal infection model [abstract A-9]. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1998 Sep 24-26; San Diego
161. Rybak MJ, Cappelletty DM, Moldovan T, et al. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42: 721-4